Evercore Maintains Outperform Rating for Insulet Corp. Despite Lowered Price Target
Evercore ISI has lowered its price target for Insulet Corp. (NASDAQ:PODD) from $340 to $240, while keeping its Outperform rating. The adjustment is part of broader revisions in the medical technology sector, following the company's voluntary medical device correction for Omnipod 5 batches due to a manufacturing flaw. The issue involved internal insulin delivery tubing, leading to 18 hospitalizations but no fatalities.
Tickers: $PODD
Topics: analyst report diabetes management medical device correction price target quality control stock rating